The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors

Prostaglandins and Other Lipid Mediators

Volumn 120, Issue , 2015, Pages 56-71

  Clapp, Lucie H ^a   Gurung, Rijan ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Beraprost; Cell proliferation; Cyclic AMP; Iloprost; Peroxisome proliferator activator receptor; Prostacyclin analogues; Prostanoid receptors; Pulmonary arterial hypertension; Treprostinil; Vascular remodelling

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLIC AMP; ILOPROST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTACYCLIN; PROSTANOID RECEPTOR; SCLEROPROTEIN; TREPROSTINIL; CELL RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL WALL; CELL PROLIFERATION; DRUG APPROVAL; DRUG EFFECT; DRUG STABILITY; DRUG TARGETING; HUMAN; LONG TERM SURVIVAL; MONOTHERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTECTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); VASCULAR REMODELING; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL MEMBRANE; DRUG EFFECTS; HYPERTENSION, PULMONARY; METABOLISM; PATHOLOGY;

ANIMALS; CELL MEMBRANE; DRUG STABILITY; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASCULAR REMODELING;

EID: 84941805219     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2015.04.007     Document Type: Review

References (227)

1. V.V. McLaughlin, S.L. Archer, D.B. Badesch, and et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 53 2009 1573 1619
2. G.E. D'Alonzo, R.J. Barst, S.M. Ayres, and et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Inter Med 115 1991 343 349
3. J. Sandoval, O. Bauerle, A. Gomez, A. Palomar, M.L. Martinez Guerra, and M.E. Furuya Primary pulmonary hypertension in children: clinical characterization and survival J Am Coll Cardiol 25 1995 466 474
4. S. Malenfant, A.S. Neyron, R. Paulin, and et al. Signal transduction in the development of pulmonary arterial hypertension Pulm Circ 3 2013 278 293
5. N.J. Davie, R.T. Schermuly, N. Weissmann, F. Grimminger, and H.A. Ghofrani The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies Eur J Clin Invest 39 Suppl. 2 2009 38 49
6. M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension J Clin Invest 122 2012 4306 4313
7. R.M. Tuder, S.L. Archer, P. Dorfmuller, and et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension J Am Coll Cardiol 62 2013 D4 D12
8. 2+ entry Am J Physiol Lung Cell Mol Physiol 292 2007 L1202 L1210
9. E. Falcetti, S.M. Hall, P.G. Phillips, and et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 182 2010 1161 1170
10. N.W. Morrell, X. Yang, P.D. Upton, and et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins Circulation 104 2001 790 795
11. T. Ogo, H.M. Chowdhury, J. Yang, and et al. Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension Am J Respir Cell Mol Biol 48 2013 733 741
12. M.G. Frid, M. Li, M. Gnanasekharan, and et al. Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall Am J Physiol Lung Cell Mol Physiol 297 2009 L1059 L1072
13. K.R. Stenmark, B. Meyrick, N. Galie, W.J. Mooi, and I.F. Mcmurtry Animal models of pulmonary arterial hypertension: The hope for etiologic discovery and pharmacologic cure Am J Physiol Lung Cell Mol Physiol 297 2009 L1013 L1032
14. P.M. Hassoun, L. Mouthon, J.A. Barbera, and et al. Inflammation, growth factors, and pulmonary vascular remodeling J Am Coll Cardiol 54 2009 S10 S19
15. J. Hiremath, S. Thanikachalam, K. Parikh, and et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial J Heart Lung Transplant 29 2010 137 149
16. J. Becker, C. ayre-Orthez, N. Frossard, and F. Pons Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 20 2006 429 447
17. I. Chazova, J.E. Loyd, V.S. Zhdanov, J.H. Newman, Y. Belenkov, and B. Meyrick Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension Am J Pathol 146 1995 389 397
18. K.R. Stenmark, and M. Rabinovitch Emerging therapies for the treatment of pulmonary hypertension Pediatr Crit Care Med 11 2010 S85 S90
19. S.S. Pullamsetti, R. Schermuly, A. Ghofrani, N. Weissmann, F. Grimminger, and W. Seeger Novel and emerging therapies for pulmonary hypertension Am J Respir Crit Care Med 189 2014 394 400
20. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
21. I. Lang, M. Gomez-Sanchez, M. Kneussl, and et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension Chest 129 2006 1636 1643
22. R.J. Barst, N. Galie, R. Naeije, and et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur Respir J 28 2006 1195 1203
23. N. Skoro-Sajer, I. Lang, and R. Naeije Treprostinil for pulmonary hypertension Vasc Health Risk Manage 4 2008 507 513
24. R. Sadushi-Kolici, N. Skoro-Sajer, D. Zimmer, and et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension J Heart Lung Transplant 31 2012 735 743
25. C.F. Opitz, R. Wensel, J. Winkler, and et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension Eur Heart J 26 2005 1895 1902
26. L. Knudsen, A. Schurawlew, N. Nickel, and et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy BMC Pulm Med 11 2011 56
27. R.J. Barst, M. McGoon, V. McLaughlin, and et al. Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2003 2119 2125
28. L.H. Clapp, and J.A. Patel The mechanistic basis for prostacyclin action in pulmonary hypertension Int J Respir Care 2010 27 33
29. 2 agonist Biochem Pharmacol 84 2012 68 75
30. N.N. Orie, A. Ledwozyw, D.J. Williams, B.J. Whittle, and L.H. Clapp Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins Prostaglandins Other Lipid Mediat 106 2013 1 7
31. L.H. Clapp, P.A. Finney, S. Turcato, S. Tran, L.J. Rubin, and A. Tinker Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery Am J Respir Cell Molec Biol 26 2002 194 201
32. J.T. Reeves, B.M. Groves, and D. Turkevich The case for treatment of selected patients with primary pulmonary hypertension Am Rev Respir Dis 134 1986 342 346
33. O. Sitbon, M. Humbert, X. Jais, and et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111
34. A.P. Fishman Pulmonary hypertension - beyond vasodilator therapy N Engl J Med 338 1998 321 322
35. V.V. McLaughlin, K.W. Presberg, R.L. Doyle, and et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 2004 78S 92S
36. E.M. Zardi, D.M. Zardi, F. Cacciapaglia, and et al. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs Int Immunopharmacol 5 2005 437 459
37. J. Kawabe, F. Ushikubi, and N. Hasebe Prostacyclin in vascular diseases - recent insights and future perspectives Circ J 74 2010 836 843
38. R.T. Schermuly, K.P. Kreisselmeier, H.A. Ghofrani, and et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension Circ Res 94 2004 1101 1108
39. J. Yang, X. Li, R.S. Al-Lamki, and et al. Smad-dependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo Circ Res 107 2010 252 262
40. M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension J Clin Invest 118 2008 2372 2379
41. C.J. Rhodes, A. Davidson, J.S. Gibbs, J. Wharton, and M.R. Wilkins Therapeutic targets in pulmonary arterial hypertension Pharmacol Ther 121 2009 69 88
42. J.A. Patel, S.M. Hall, D.J. Abraham, A.C. Nelsen, A.M. Silverstein, and L.H. Clapp Comparison of current therapies to inhibit endothelin-induced growth of pulmonary artery smooth muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Eur Respir J 44 Suppl. 58 2014 P2355
43. S.M. Hall, N. Davie, N. Klein, and S.G. Haworth Endothelin receptor expression in IPAH: effect of bosentan and epoprostenol treatment Eur Respir J 38 2011 851 860
44. B receptors in cardiovascular disease Annu Rev Pharmacol Toxicol 47 2007 731 759
45. S.J. Wort, M. Woods, T.D. Warner, T.W. Evans, and J.A. Mitchell Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling Am J Respir Cell Mol Biol 25 2001 104 110
46. L.K. Kelly, S. Wedgwood, R.H. Steinhorn, and S.M. Black Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase Am J Physiol Lung Cell Mol Physiol 286 2004 L984 L991
47. R.J. Gryglewski Prostacyclin among prostanoids Pharmacol Rep 60 2008 3 11
48. J.A. Jakubowski, B.G. Utterback, D.E. Mais, and et al. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets Prostaglandins 47 1994 189 201
49. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structure, properties, and functions Physiol Rev 79 1999 1193 1226
50. P.G. Phillips, L. Long, M.R. Wilkins, and N.W. Morrell cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling Am J Physiol Lung Cell Mol Physiol 288 2005 L103 L115
51. F. Murray, H.H. Patel, R.Y. Suda, and et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1 Am J Physiol Lung Cell Mol Physiol 292 2007 L294 L303
52. R.T. Schermuly, S.S. Pullamsetti, S.C. Breitenbach, and et al. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs Respir Res 8 2007 4
53. T. Murata, F. Ushikubi, T. Matsuoka, and et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature (London) 388 1997 678 682
54. L.J. Rubin, B.M. Groves, J.T. Reeves, M. Frosolono, F. Handel, and A.E. Cato Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension Circulation 66 1982 334 338
55. D.K. Jones, T.W. Higenbottam, and J. Wallwork Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin) Br Heart J 57 1987 270 278
56. R.J. Gryglewski Effects of prostacyclin in atherosclerotic vascular disease Adv Prostaglandin Thromboxane Leukot Res 15 1985 539 542
57. M. Fredrich, and B. Muller Prostacyclin and atherosclerosis G.M. Rubanyi, J.R. Vane, Prostacyclin: new prospectives for basic research and novel therapeutic indications 1992 Elsevier Science Publishers 169 180
58. Y. Numaguchi, K. Naruse, M. Harada, and et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury Arterioscler Thromb Vasc Biol 19 1999 727 733
59. T. Todaka, C. Yokoyama, H. Yanamoto, and et al. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats Stroke 30 1999 419 426
60. S. Hara, R. Morishita, Y. Tone, and et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells Biochem Biophys Res Commun 216 1995 862 867
61. C. Yokoyama, T. Yabuki, M. Shimonishi, and et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction Circulation 106 2002 2397 2403
62. K.M. Egan, J.A. Lawson, S. Fries, and et al. COX-2-derived prostacyclin confers atheroprotection on female mice Science 306 2004 1954 1957
63. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice J Clin Invest 114 2004 784 794
64. Y. Hoshikawa, N.F. Voelkel, T.L. Gesell, and et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling Am J Respir Crit Care Med 164 2001 314 318
65. 2 receptor Circulation 112 2005 84 92
66. H. Francois, K. Athirakul, D. Howell, and et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis Cell Metab 2 2005 201 207
67. 2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling Arterioscler Thromb Vasc Biol 30 2010 464 470
68. Y. Aburakawa, J. Kawabe, M. Okada, and et al. Prostacyclin stimulated integrin-dependent angiogenic effects of endothelial progenitor cells and mediated potent circulation recovery in ischemic hind limb model Circ J 77 2013 1053 1062
69. B.J. Whittle, and S. Moncada Antithrombotic assessment and clinical potential of prostacyclin analogues G.P. Ellis, G.B. West, Progress in medical chemistry 1984 Elsevier Science Publishers North Holland 237 279
70. J.L. Demolis, A. Robert, M. Mouren, C. Funck-Brentano, and P. Jaillon Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers J Cardiovasc Pharmacol 22 1993 711 716
71. H. Olschewski, F. Rose, R. Schermuly, and et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension Pharmacol Ther 102 2004 139 153
72. M. Wade, F.J. Baker, R. Roscigno, and et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion J Clin Pharmacol 44 2004 503 509
73. 2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor Prostaglandins Other Lipid Mediat 107 2013 48 55
74. N. Skoro-Sajer, and I.M. Lang Selexipag for the treatment of pulmonary arterial hypertension Expert Opin Pharmacother 15 2014 429 436
75. K. Kuwano, A. Hashino, T. Asaki, and et al. 2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug J Pharmacol Exp Ther 322 2007 1181 1188
76. K. Morrison, R. Studer, R. Ernst, F. Haag, K. Kauser, and M. Clozel Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery J Pharmacol Exp Ther 343 2012 547 555
77. D.F. Woodward, R.L. Jones, and S. Narumiya International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress Pharmacol Rev 63 2011 471 538
78. I. Kennedy, R.A. Coleman, P.P. Humphrey, G.P. Levy, and P. Lumley Studies on the characterisation of prostanoid receptors: a proposed classification Prostaglandins 24 1982 667 689
79. R.A. Lawrence, R.L. Jones, and N.H. Wilson Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum Br J Pharmacol 105 1992 271 278
80. 2 analogues are non-selective prostanoid antagonists in rat and human stomach muscle Br J Pharmacol 77 1982 591 596
81. 1α: implication of dosage in patients with primary pulmonary hypertension Anal Chem 74 2002 3892 3898
82. X. Norel Prostanoid receptors in the human vascular wall Sci World J 7 2007 1359 1374
83. 4 receptor subtype Br J Pharmacol 154 2008 1631 1639
84. 2 Science 296 2002 539 541
85. 2 receptor agonist cicaprost via a cyclic AMP-independent mechanism Cardiovasc Res 69 2006 107 115
86. 3 receptors Eur J Pharmacol 654 2011 258 265
87. S. Ibrahim, A. McCartney, N. Markosyan, and E.M. Smyth Heterodimerization with the prostacyclin receptor triggers thromboxane receptor relocation to lipid rafts Arterioscler Thromb Vasc Biol 33 2013 60 66
88. G. Hansmann, R.A. Wagner, S. Schellong, and et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation Circulation 115 2007 1275 1284
89. M. Abramovitz, M. Adam, Y. Boie, and et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs Biochim Biophys Acta 1483 2000 285 293
90. + channels play a major role in mediating the vascular effects of iloprost and cicaprost Eur J Pharmacol 356 1998 215 224
91. R.T. Schermuly, S.S. Pullamsetti, G. Kwapiszewska, and et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy Circulation 115 2007 2331 2339
92. S. Mizuguchi, T. Ohno, Y. Hattori, and et al. Roles of prostaglandin E2-EP1 receptor signaling in regulation of gastric motor activity and emptying Am J Physiol Gastrointest Liver Physiol 299 2010 G1078 G1086
93. 4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension Am J Respir Crit Care Med 178 2008 188 196
94. W. Krause, and T. Krais Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man Eur J Clin Pharmacol 30 1986 61 68
95. D.M. Aronoff, C.M. Peres, C.H. Serezani, and et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities J Immunol 178 2007 1628 1634
96. 1 activity Prostaglandins Leukot Essent Fatty Acids 95 2015 19 29
97. C.S. McSwain, R. Benza, S. Shapiro, and et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion J Clin Pharmacol 48 2008 19 25
98. Y. Gao, and J.U. Raj Role of veins in regulation of pulmonary circulation Am J Physiol Lung Cell Mol Physiol 288 2005 L213 L226
99. X. Norel, L. Walch, C. Labat, J.P. Gascard, E. Dulmet, and C. Brink Prostanoid receptors involved in the relaxation of human bronchial preparations Br J Pharmacol 126 1999 867 872
100. 4) agonists: potent dilators of human bronchi and future asthma therapy Pulm Pharmacol Ther 25 2012 115 118
101. 3 receptors J Pharmacol Exp Ther 336 2011 391 402
102. K. Hubertus, M. Mischnik, J. Timmer, and et al. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors Eur J Pharmacol 740 2014 15 27
103. F.Y. Ali, S.J. Davidson, L.A. Moraes, and et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ FASEB J 20 2006 326 328
104. 2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling Am J Physiol Lung Cell Mol Physiol 292 2007 L405 L413
105. 2+ concentrations in human airway smooth muscle cells Eur J Pharmacol 659 2011 72 78
106. 2 E-prostanoid 2 receptor exacerbates vascular neointimal formation in mice Arterioscler Thromb Vasc Biol 31 2011 1739 1747
107. 2 inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity Am J Respir Cell Mol Biol 32 2005 135 141
108. 2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation Am J Respir Cell Mol Biol 29 2003 537 544
109. 2 J Immunol 174 2005 5644 5649
110. K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery J Pharmacol Exp Ther 326 2008 691 699
111. K. Morrison, R. Ernst, P. Hess, R. Studer, and M. Clozel Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function J Pharmacol Exp Ther 335 2010 249 255
112. 2 Br J Pharmacol 162 2011 521 531
113. Y.J. Zhao, J. Wang, M.L. Tod, L.J. Rubin, and X.J. Yuan Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors J Appl Physiol 81 1996 2595 2603
114. W.L. Smith, D.L. DeWitt, and M.L. Allen Bimodal distribution of the prostaglandin I2 synthase antigen in smooth muscle cells J Biol Chem 258 1983 5922 5926
115. H. Lim, and S.K. Dey A novel pathway of prostacyclin signaling-hanging out with nuclear receptors Endocrinology 143 2002 3207 3210
116. Z.S. Katusic, A.V. Santhanam, and T. He Vascular effects of prostacyclin: does activation of PPARdelta play a role Trends Pharmacol Sci 33 2012 559 564
117. 2 is a ligand for the adipocyte determination factor PPAR γ Cell 83 1995 803 812
118. B.M. Forman, J. Chen, and R.M. Evans Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta Proc Natl Acad Sci U S A 94 1997 4312 4317
119. L. Jin, S. Lin, H. Rong, and et al. Structural basis for iloprost as a dual peroxisome proliferator-activated receptor α/δ agonist J Biol Chem 286 2011 31473 31479
120. H. Lin, J.L. Lee, H.H. Hou, C.P. Chung, S.P. Hsu, and S.H. Juan Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells J Cell Physiol 214 2008 434 441
121. R. Pola, E. Gaetani, A. Flex, and et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors J Mol Cell Cardiol 36 2004 363 370
122. R. Nemenoff, A.M. Meyer, T.M. Hudish, and et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ Cancer Prev Res 1 2008 349 356
123. T. He, T. Lu, L.V. d'Uscio, C.F. Lam, H.C. Lee, and Z.S. Katusic Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells Circ Res 103 2008 80 88
124. J.C. Huang, W.S. Wun, J.S. Goldsby, K. Egan, G.A. FitzGerald, and K.K. Wu Prostacyclin receptor signaling and early embryo development in the mouse Hum Reprod 22 2007 2851 2856
125. E. Falcetti, D.M. Flavell, B. Staels, A. Tinker, S.G. Haworth, and L.H. Clapp IP receptor-dependent activation of PPARγ by stable prostacyclin analogues Biochem Biophys Res Commun 360 2007 821 827
126. G. Lazennec, L. Canaple, D. Saugy, and W. Wahli Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators Mol Endocrinol 14 2000 1962 1975
127. M. Hamblin, L. Chang, Y. Fan, J. Zhang, and Y.E. Chen PPARs and the cardiovascular system Antioxid Redox Signal 11 2009 1415 1452
128. J. Wang, K. Yang, L. Xu, and et al. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis Am J Respir Cell Mol Biol 49 2013 231 240
129. S. Turcato, and L.H. Clapp The effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cAMP elevation in isolated guinea-pig aorta Br J Pharmacol 126 1999 845 847
130. R.E. Nisbet, R.L. Sutliff, and C.M. Hart The role of peroxisome proliferator-activated receptors in pulmonary vascular disease PPAR Res 2007 2007 18797
131. Y. Li, M. Connolly, C. Nagaraj, and et al. Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation Am J Respir Cell Mol Biol 46 2012 372 379
132. G. Liu, X. Li, Y. Li, and et al. PPARdelta agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling Biomed Res Int 2013 2013 903947
133. W. Linz, P. Wohlfart, M. Baader, and et al. The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats Acta Pharmacol Sin 30 2009 935 946
134. R. Jimenez, M. Sanchez, M.J. Zarzuelo, and et al. Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway J Pharmacol Exp Ther 332 2010 554 561
135. R.E. Nisbet, J.M. Bland, D.J. Kleinhenz, and et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model Am J Respir Cell Mol Biol 42 2010 482 490
136. H. Kozlowska, M. Baranowska-Kuczko, E. Schlicker, M. Kozlowski, M. Kloza, and B. Malinowska Relaxation of human pulmonary arteries by PPARγ agonists Naunyn Schmiedebergs Arch Pharmacol 386 2013 445 453
137. D.E. Green, R.L. Sutliff, and C.M. Hart Is peroxisome proliferator-activated receptor γ (PPARγ) a therapeutic target for the treatment of pulmonary hypertension Pulm Circ 1 2011 33 47
138. Y. Liu, X.Y. Tian, Y. Huang, and N. Wang Rosiglitazone Attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors PPAR Res 2014 2014 374075
139. 3 receptors Am J Respir Crit Care Med 2015 (in press)
140. S. Eddahibi, M. Humbert, S. Sediame, and et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy Am J Respir Crit Care Med 162 2000 1493 1499
141. F. Biscetti, E. Gaetani, A. Flex, and et al. Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation J Vasc Res 46 2009 103 108
142. M.M. Hoper, N.F. Voelkel, T.O. Bates, and et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP Am J Respir Cell Mol Biol 17 1997 748 756
143. H. Atsuta, T. Uchiyama, H. Kanai, T. Iso, T. Tanaka, T. Suga, T. Maeno, M. Arai, and et al. Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells Int J Cardiol 132 2009 411 418
144. L. Piqueras, A.R. Reynolds, K.M. Hodivala-Dilke, and et al. Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis Arterioscler Thromb Vasc Biol 27 2007 63 69
145. J. Wang, R. Ikeda, X.F. Che, and et al. VEGF expression is augmented by hypoxiainduced PGIS in human fibroblasts Int J Oncol 43 2013 746 754
146. H. He, V.J. Venema, X. Gu, R.C. Venema, M.B. Marrero, and R.B. Caldwell Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src J Biol Chem 274 1999 25130 25135
147. H. Iwaguro, J. Yamaguchi, C. Kalka, and et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration Circulation 105 2002 732 738
148. D.M. Smadja, L. Mauge, P. Gaussem, and et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension Angiogenesis 14 2011 17 27
149. S.R. Di, M.C. Barsotti, E. Melillo, and et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia Thromb Haemost 100 2008 871 877
150. M. Murakami, M. Watanabe, H. Furukawa, and H. Nakahara The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study Ann Vasc Surg 19 2005 838 842
151. S. Berman, R. Quick, P. Yoder, S. Voigt, D. Strootman, and M. Wade Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study Vascular 14 2006 142 148
152. J. Pope Treatment of systemic sclerosis Curr Opin Rheumatol 5 1993 792 801
153. J.J. Belch, M. McLaren, C.S. Lau, and et al. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers Br J Clin Pharmacol 35 1993 643 647
154. F. Biscetti, E. Gaetani, A. Flex, and et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)α and PPAR γ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism Diabetes 57 2008 1394 1404
155. S. Ameshima, H. Golpon, C.D. Cool, and et al. Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth Circ Res 92 2003 1162 1169
156. C. Guignabert, C.M. Alvira, T.P. Alastalo, and et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-γ in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization Am J Physiol Lung Cell Mol Physiol 297 2009 L1082 L1090
157. M.C. Tsai, L. Chen, J. Zhou, and et al. Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells Circ Res 105 2009 471 480
158. H.M. Yang, B.K. Kim, J.Y. Kim, and et al. PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury Exp Mol Med 45 2013 e65
159. M. Ding, A.C. Carrao, R.J. Wagner, and et al. Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype J Mol Cell Cardiol 52 2012 474 484
160. J. Wharton, N. Davie, P.D. Upton, M.H. Yacoub, J.M. Polak, and N.W. Morrell Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells Circulation 102 2000 3130 3136
161. H. Ohtsubo, T. Ichiki, R. Miyazaki, and et al. Inducible cAMP early repressor inhibits growth of vascular smooth muscle cell Arterioscler Thromb Vasc Biol 27 2007 1549 1555
162. D. Kothapalli, S.A. Stewart, E.M. Smyth, I. Azonobi, E. Pure, and R.K. Assoian Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression Mol Pharmacol 64 2003 249 258
163. M. Kadowaki, S. Mizuno, Y. Demura, S. Ameshima, I. Miyamori, and T. Ishizaki Effect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1 Respir Res 8 2007 77
164. Y.M. Sue, C.P. Chung, H. Lin, and et al. PPARδ-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells Am J Physiol Cell Physiol 297 2009 C321 C329
165. Y. Chen, S. Yang, W. Yao, and et al. Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF beta-Smad signal pathway PLOS ONE 9 2014 e98483
166. + channels J.X. Yuan, Ion channels in the pulmonary vasculature 2005 Taylor & Francis Boca Raton 257 286
167. A. Olschewski, R. Papp, C. Nagaraj, and H. Olschewski Ion channels and transporters as therapeutic targets in the pulmonary circulation Pharmacol Ther 144 2014 349 368
168. R.I. Jabr, A.J. Wilson, M.H. Riddervold, A.H. Jenkins, B.A. Perrino, and L.H. Clapp Nuclear translocation of calcineurin Aβ but not calcineurin Aα by platelet-derived growth factor in rat aortic smooth muscle Am J Physiol 292 2007 C2213 C2225
169. S. Bonnet, G. Rochefort, G. Sutendra, and et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted Proc Natl Acad Sci U S A 104 2007 11418 11423
170. T. Morimoto, K. Hasegawa, H. Wada, and et al. Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes J Biol Chem 276 2001 34983 34989
171. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells Am J Respir Crit Care Med 165 2002 398 405
172. P. Rehberger, P. Beckheinrich-Mrowka, U.F. Haustein, and M. Sticherling Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations Acta Derm Venereol 89 2009 245 249
173. F.Y. Ali, K. Egan, G.A. FitzGerald, and et al. Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts Am J Respir Cell Mol Biol 34 2006 242 246
174. S. Han, J.D. Ritzenthaler, X. Sun, Y. Zheng, and J. Roman Activation of peroxisome proliferator-activated receptor β/δ induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha Am J Respir Cell Mol Biol 40 2009 325 331
175. L.S. Harrington, L. Moreno, A. Reed, and et al. The PPARβ/δ agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension PLoS ONE 5 2010 e9526
176. B.W. Christman, C.D. McPherson, J.H. Newman, and et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 1992 70 75
177. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease Circulation 88 1993 2117 2122
178. 2 and prostacyclin Am J Med Genet A 152A 2010 1919 1924
179. R.M. Tuder, C.D. Cool, M.W. Geraci, and et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am J Respir Crit Care Med 159 1999 1925 1932
180. C.N. Mahajan, A.J. Afolayan, A. Eis, R.J. Teng, and G.G. Konduri Altered prostanoid metabolism contributes to impaired angiogenesis in persistent pulmonary hypertension in a fetal lamb model Pediatr Res 77 2015 455 462
181. M.W. Geraci, B. Gao, D.C. Shepherd, and et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension J Clin Invest 103 1999 1509 1515
182. N. Nagaya, C. Yokoyama, S. Kyotani, and et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats Circulation 102 2000 2005 2010
183. W. Zhou, D.R. Dowell, M.W. Geraci, and et al. PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression Am J Physiol Lung Cell Mol Physiol 301 2011 L615 L622
184. R.S. Stearman, A.R. Cornelius, X. Lu, and et al. Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension Am J Respir Crit Care Med 189 2014 1110 1120
185. S. Ibrahim, M. Tetruashvily, A.J. Frey, and et al. Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease Arterioscler Thromb Vasc Biol 30 2010 1802 1809
186. M.R. Wilkins, J. Wharton, F. Grimminger, and H.A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur Respir J 32 2008 198 209
187. N. Begum, S. Hockman, and V.C. Manganiello Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins J Biol Chem 286 2011 26238 26249
188. E.A. Bowles, G.N. Moody, Y. Yeragunta, A.H. Stephenson, M.L. Ellsworth, and R.S. Sprague Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension Exp Biol Med 240 2015 121 127
189. M. Laflamme, L.P. Perrault, M. Carrier, M. Elmi-Sarabi, A. Fortier, and A.Y. Denault Preliminary experience with combined inhaled milrinone and prostacyclin in cardiac surgical patients with pulmonary hypertension J Cardiothorac Vasc Anesth 29 2015 38 45
190. K.A. Resnick, and I.L. Gordon Effects of cilostazol on arterial wound healing: a retrospective analysis Ann Vasc Surg 28 2014 1513 1521
191. X. Tian, C. Vroom, H.A. Ghofrani, and et al. Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling PLoS ONE 6 2011 e18136
192. K.J. Bubb, S.L. Trinder, R.S. Baliga, and et al. Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension Circulation 2014
193. E.M. Smyth, W.H. Li, and G.A. FitzGerald Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c J Biol Chem 273 1998 23258 23266
194. A. Sobolewski, K.B. Jourdan, P.D. Upton, L. Long, and N.W. Morrell Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase Am J Physiol Lung Cell Mol Physiol 287 2004 L352 L359
195. 2 receptor is a target for prostacyclin-mediated desensitization J Biol Chem 275 2000 20412 20423
196. O. Kowal-Bielecka, K. Kowal, O. Distler, and et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators Arthritis Rheum 52 2005 3783 3791
197. R.B. Penn, R.M. Pascual, Y.M. Kim, and et al. Arrestin specificity for G protein-coupled receptors in human airway smooth muscle J Biol Chem 276 2001 32648 32656
198. S.P. Lakshmi, A.T. Reddy, Y. Zhang, and et al. Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD) J Biol Chem 289 2014 6383 6393
199. X. Lu, K.M. Bijli, A. Ramirez, T.C. Murphy, J. Kleinhenz, and C.M. Hart Hypoxia downregulates PPARγ via an ERK1/2-NF-kappaB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells Free Radic Biol Med 63 2013 151 160
200. G. Hansmann, V. de Jesus Perez, T.P. Alastalo, and et al. An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertension J Clin Invest 118 2008 1846 1857
201. L. Benayoun, S. Letuve, A. Druilhe, and et al. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling Am J Respir Crit Care Med 164 2001 1487 1494
202. Z. Czimmerer, T. Varga, S. Poliska, I. Nemet, A. Szanto, and L. Nagy Identification of novel markers of alternative activation and potential endogenous PPARγ ligand production mechanisms in human IL-4 stimulated differentiating macrophages Immunobiology 217 2012 1301 1314
203. C. Li, M.S. Mpollo, C.S. Gonsalves, S.M. Tahara, P. Malik, and V.K. Kalra Peroxisome proliferator-activated receptor-alpha-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1alpha J Biol Chem 289 2014 36031 36047
204. S.Z. Duan, M.G. Usher, and R.M. Mortensen PPARs: the vasculature, inflammation and hypertension Curr Opin Nephrol Hypertens 18 2009 128 133
205. J. Yang, R.J. Davies, M. Southwood, and et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension Circ Res 102 2008 1212 1221
206. A. Chida, M. Shintani, H. Yagi, and et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers Am J Cardiol 110 2012 586 593
207. B. Kojonazarov, H. Luitel, A. Sydykov, and et al. The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy Pulm Circ 3 2013 926 935
208. M.E. van Albada, R.M. Berger, M. Niggebrugge, V.R. van, A.H. Cromme-Dijkhuis, and R.G. Schoemaker Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension Eur J Pharmacol 549 2006 107 116
209. S. Hall, P. Brogan, S.G. Haworth, and N. Klein Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children Thorax 64 2009 778 783
210. E.S. Klings, B.D. Anton, D. Rosenman, and et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression Am J Hematol 83 2008 547 553
211. F. Sakamaki, S. Kyotani, N. Nagaya, and et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy Circulation 102 2000 2720 2725
212. 2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus Metabolism 52 2003 192 198
213. C.M. Riva, M.L. Morganroth, A.G. Ljungman, and et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers Am J Respir Cell Mol Biol 3 1990 301 309
214. 2 controls the migration of eosinophils J Allergy Clin Immunol 125 2010 1105 1113
215. A.A. Birukova, T. Wu, Y. Tian, and et al. Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury Eur Respir J 41 2013 165 176
216. M. Braun, P. Pietsch, A. Zepp, K. Schror, G. Baumann, and S.B. Felix Regulation of tumor necrosis factor α- and interleukin-1-β-induced induced adhesion molecule expression in human vascular smooth muscle cells by cAMP Arterioscler Thromb Vasc Biol 17 1997 2568 2575
217. B. Raychaudhuri, A. Malur, T.L. Bonfield, and et al. The prostacyclin analogue treprostinil blocks NFκB nuclear translocation in human alveolar macrophages J Biol Chem 277 2002 33344 33348
218. M.K. Tsai, C.C. Hsieh, H.F. Kuo, and et al. Effect of prostaglandin I analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage Clin Exp Med 2014 10.1007/s10238-014-0304-7
219. 2 analogues suppress TNF-α expression in human monocytes via mitogen-activated protein kinase pathway Inflamm Res 60 2011 655 663
220. 2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells J Immunol 178 2007 702 710
221. 2 analogs inhibit Th1 and Th2 effector cytokine production by CD4T cells J Leukoc Biol 81 2007 809 817
222. R.M. Di, D. Pieragalli, S. Meini, and et al. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6 Prostaglandins Leukot Essent Fatty Acids 73 2005 405 410
223. H. Katsushi, N. Kazufumi, F. Hideki, and et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension Circ J 68 2004 227 231
224. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells Br J Pharmacol 122 1997 217 224
225. 3H]-prostacyclin to membranes of a neuronal somatic hybrid Br J Pharmacol 72 1981 435 441
226. 2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects Br J Clin Pharmacol 15 1983 77 81
227. 4 prostanoid receptor Br J Pharmacol 130 2000 1919 1926